AR and prostate adenocarcinoma: In another example, loss of RB1 and TP53 function in prostate adenocarcinomas enables lineage plasticity of androgen receptor (AR)-dependent luminal epithelial cells, allowing them to shift into AR-independent basal-like cells, and thus gain resistance to targeted anti-androgen drugs [62,63].